DTB: Vol 24, No 4

New antidiabetic drugs: What place should they have in therapeutics?

The long-term effectiveness and safety profile of new antidiabetics is still to be established due to the short duration of the trials performed so far. No evidence has been published to demonstrate that new antidiabetics improve the incidence of cardiovascular complications and/or mortality. Metformin is the oral antidiabetic of choice in patients with diabetes mellitus type 2 whose blood glucose levels are not satisfactorily controlled on diet and exercise alone.

Authors:

  • Mª José Ariz. General Practitioner. Navarre Health Service. Spain
  • Gabriela Elizondo. Head of pharmacovigilance. Health Department. Government of Navarre. Spain
Responsive Image